Treating severe acne. It may also be used for other conditions as determined by your doctor.
Clindamycin phosphate is a topical lincomycin antibiotic. It works by killing sensitive bacteria that cause acne and reducing the amount of free fatty acids that irritate the skin surface.
Clindamycin phosphate indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Clindamycin phosphate, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.
Clindamycin phosphate, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the ï»¿WARNINGï»¿ box, before selecting clindamycin the physician should considere the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.
Indicated surgical procedures should be performed in conjunction with antibiotic therapy.
Clindamycin phosphate, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below:
Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, ï»¿Streptococcus pneumoniae, ï»¿other streptococci (except ï»¿E. faecalisï»¿), and ï»¿Staphylococcus aureus.
ï»¿Skin and skin structure infections caused by ï»¿Streptococcus pyogenes, Staphylococcus aureus, ï»¿and anaerobes.
Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.
Intra-abdominal infections including acute hematogenous osteomyelitis caused by ï»¿Staphylococcus aureusï»¿ and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.
Septicemia caused by ï»¿Staphylococcus aureus, ï»¿streptococci (except ï»¿Enterococcus faecalisï»¿), and susceptible anaerobes.
Bone and joint infections including acute hematogenous osteomyelitis caused by ï»¿Staphylococcus aureusï»¿ and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Clindamycin phosphate?
Use Clindamycin phosphate as directed by your doctor. Check the label on the medicine for exact dosing instructions.
An extra patient leaflet is available with Clindamycin phosphate. Talk to your pharmacist if you have questions about this information.
Clindamycin phosphate is for topical use on the skin only.
Wash the affected areas to be treated with mild soap and water and allow the skin to dry thoroughly.
To use Clindamycin phosphate, hold the can upright and dispense the amount of medicine to be used directly into the cap or onto a cool surface. Pick up small amounts of the foam with your fingertips and gently massage it into the affected areas until the foam disappears.
If the can seems warm or the foam seems runny, hold the can under cold running water to cool it. Do not dispense the medicine directly onto your skin or hands because it will melt too soon.
Throw away any unused medicine that has been dispensed out of the can.
Wash your hands immediately after using Clindamycin phosphate.
Use Clindamycin phosphate on a regular schedule to get the most benefit from it.
If you miss a dose of Clindamycin phosphate, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Clindamycin phosphate.
Uses of Clindamycin phosphate in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
This medication is used to treat acne. It helps to decrease the number of acne lesions. Clindamycin is an antibiotic which works by stopping the growth of bacteria.
How to use Clindamycin phosphate topical
Use this medication only on the skin. Clean and dry the affected area first. Follow all directions on the product package, or use as directed by your doctor.
If you are using the lotion, shake the bottle well before using. Apply a thin layer of medication usually twice a day or as directed by your doctor.
If you are using the medicated pad or swab, apply to the the affected area gently with it, then discard. Depending on the size of the area to be treated, more than one pad or swab may be necessary.
If you are using the foam, apply it once daily to the affected areas. Use enough to cover the entire affected area. Do not spray the foam directly onto your hands or face, because the foam will begin to melt on contact with warm skin. Instead spray the amount needed directly into the cap or onto a cool surface such as a counter top. If the can seems warm or the foam seems runny, run the can under cold water. Please read the patient information leaflet available from your pharmacist for specific instructions on how to use the foam, and ask about any information that is unclear.
Wash your hands after use.
Avoid contact with your eyes, nose, mouth or any areas of broken skin. If you accidentally get medication in these areas, rinse well with plenty of cool water.
It may take between 2-6 weeks to notice an improvement in your condition, and up to 12 weeks to see the full benefit.
Inform your doctor if your condition does not improve or worsens.
Clindamycin phosphate description
Each mL of Dalacin T
Topical Solution contains clindamycin phosphate 10 mg. Dalacin T
Topical Solution also contains the following excipients: Isopropyl alcohol, propylene glycol, hydrochloric acid, sodium hydroxide and water.
Each mL of Dalacin T
Topical Lotion contains clindamycin 10 mg. Dalacin T
Topical Lotion also contains the following excipients: Glycerol, sodium lauroyl sarcosinate, stearic acid, glyceryl stearate SE (with potassium monostearate), cetostearyl alcohol, isostearyl alcohol, methylparaben and water.
Each topical gel contains clindamycin phosphate at a concentration equivalent to clindamycin 10 mg/g. Dalacin T
Topical Gel also contains the following excipients: Allantoin, carbomer 934P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide and purified water.
Clindamycin phosphate is a water-soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic, lincomycin.
The chemical name for Clindamycin phosphate is 7(S)-chloro-7-deoxylincomycin-2-phosphate. It has a molecular formula of C18H34ClN2O8PS and a molecular weight of 504.96.
Clindamycin phosphate dosage
Apply a thin film of Clindamycin phosphate
Topical Solution twice daily to affected area. Keep all liquid dosage forms in containers tightly closed.
Topical Solution, USP 1%
containing Clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following sizes:
30 mL applicator bottles - NDC 0472-0987-91
60 mL applicator bottles - NDC 0472-0987-92
Store at 20°-25°C (68°-77°F). Protect from freezing.
Inform the physician or pharmacist if the patient is taking or has recently taken other medication (ie, with/without prescription). The solution and lotion of Dalacin T should not be used concomitantly with any skin treatment containing benzoyl peroxide.
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.
Warfarin or similar medicines-used to thin the blood. The patient may be more likely to have a bleed. The physician may need to take regular blood tests to check how well the blood can clot.
In clinical trials involving non-pregnant women, 1.8% of 600 patients who received treatment with Clindamycin phosphate vaginal cream 2% for 3 days and 2.7% of 1325 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered Clindamycin phosphate vaginal cream 2%, were reported for 20.7% of the patients receiving treatment for 3 days and 21.3% of the patients receiving treatment for 7 days. Events occurring in ≥1% of patients receiving Clindamycin phosphate vaginal cream 2% are shown in Table 1.
TABLE 1 – Events Occurring in ≥1% of Non-pregnant Patients Receiving Clindamycin phosphate Vaginal Cream 2%
Clindamycin phosphate Vaginal Cream
Body as a Whole
Other events occurring in <1% of the Clindamycin phosphate 2% groups include:
In a clinical trial involving pregnant women during the second trimester, 1.7% of 180 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered Clindamycin phosphate vaginal cream 2%, were reported for 22.8% of pregnant patients. Events occurring in ≥1% of patients receiving either Clindamycin phosphate vaginal cream 2% or placebo are shown in Table 2.
TABLE 2 - Events Occurring in ≥1% of Pregnant Patients Receiving Clindamycin phosphate Vaginal Cream 2% or Placebo
Clindamycin phosphate Vaginal Cream
Body as a Whole
Pruritus, non-application site
Other events occurring in <1% of the Clindamycin phosphate 2% group include:
Urogenital system: dysuria, metrorrhagia, vaginal pain, and trichomonal vaginitis.
Body as a whole: upper respiratory infection.
Skin: pruritus (topical application site) and erythema.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
In the post-marketing period, there have been case reports of pseudomembranous colitis with the use of Clindamycin phosphate vaginal cream.
Other clindamycin formulations
Clindamycin phosphate affords minimal peak serum levels and systemic exposure (AUCs) of clindamycin compared to 100 mg oral clindamycin dosing. Although these lower levels of exposure are less likely to produce the common reactions seen with oral clindamycin, the possibility of these and other reactions cannot be excluded presently. Data from well-controlled trials directly comparing clindamycin administered orally to clindamycin administered vaginally are not available.
The following adverse reactions and altered laboratory tests have been reported with the oral or parenteral use of clindamycin:
Gastrointestinal: Abdominal pain, esophagitis, nausea, vomiting, diarrhea and pseudomembranous colitis.
Hematopoietic: Transient neutropenia (leukopenia), eosinophilia, agranulocytosis, and thrombocytopenia have been reported. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of these reports.
Hypersensitivity Reactions: Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions. Rare instances of erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with clindamycin. A few cases of anaphylactoid reactions have been reported. If a hypersensitivity reaction occurs, the drug should be discontinued.
Liver: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.
Musculoskeletal: Rare instances of polyarthritis have been reported.
Renal: Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances.
Clindamycin phosphate topical solution, Clindamycin phosphate topical gel and Clindamycin phosphate topical lotion are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.
Active ingredient matches for Clindamycin phosphate:
Unit description / dosage (Manufacturer)
30 gram in 1 tube
60 gram in 1 tube
60 milliliter in 1 bottle
30 milliliter in 1 bottle, with applicator
60 milliliter in 1 bottle, with applicator
Clindamycin Phosphate gel 10 mg/g (Greenstone LLC (US))
The results of a survey conducted on ndrugs.com for Clindamycin phosphate are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Clindamycin phosphate. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
1 consumer reported age
There are no reviews yet. Be the first to write one!